Skip to Content

Generic Targretin Gel Availability

Targretin Gel is a brand name of bexarotene topical, approved by the FDA in the following formulation(s):

TARGRETIN (bexarotene - gel;topical)

  • Manufacturer: VALEANT LUXEMBOURG
    Approval date: June 28, 2000
    Strength(s): 1% [RLD]

Has a generic version of Targretin Gel been approved?

An Authorized Generic version of Targretin Gel has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance, and unlike a generic, the Authorized Generic has exactly the same inactive ingredients.

List of authorized generic versions:

  • bexarotene TOPICAL GEL 1 g/100g
    Oceanside Pharmaceuticals
    NDC Code: 686820002

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Targretin Gel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
    Patent 5,962,731
    Issued: October 5, 1999
    Inventor(s): Boehm; Marcus F. & Heyman; Richard A.
    Assignee(s): Ligand Pharmaceuticals Incorporated
    Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
    Patent expiration dates:
    • October 5, 2016
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.